An Industry Perspective on Working with CROs
Biotech and biopharmaceutical companies are increasingly faced with pressure to produce results with ever shrinking timelines and budget. A growing trend for these companies to cope with this pressure is to leverage external resources and expertise by outsourcing research activities to contract research organizations (CROs). Although traditionally large scale manufacturing and clinical trials are quite often outsourced due to lack of internal resources, more and more companies are outsourcing earlier stage research and development activities.
Although outsourcing drug development activity promises savings of time and cost in the development of new drugs and devices, it also presents new potential risks.
In this session, a panel of experts with different perspectives will explore industry perspective on outsourcing. Topics for discussion include:
- Reasons for outsourcing: simple cost saving vs. gaining external expertise
- Reasons for not outsourcing: what are the major pitfalls of working in a virtual environment?
- How to determine what constitute internal core competency vs. external resources
- Small and local vs. big and global CROs
- What are key elements for successful project completion?
- What resources would you like to see out there that you can't find
- San Diego as a CRO hub
Paul Steinberg, Director, Business Development & Client Services, Novella Clinical
Pierre Corin, Senior Director of Development, Cerexa
David Donahue, Senior Director, Head, Clinical Operations, Auspex Pharmaceuticals
Rosa Luo, M.S., Manager, Drug Metabolism & Pharmacokinetics, Neurocrine Biosciences
Linda Strause, Ph.D., Executive Director and Head of Clinical Operations, Vical
|When||Thursday, June 28, 2012
8:00 a.m. - 10:00 a.m.
Add to Calendar
|RSVP||Wednesday, June 20, 2012 12:00 p.m.|
4510 Executive Drive Plaza 7
San Diego, CA 92121
Get Driving Directions